Latest market price
4.32
+0.01+0.23%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -0.04 | Insider Own | 49.13% | Shs Outstand | 531.16M | Perf Week | -5.48% |
| Market Cap | 2.29B | Forward P/E | 42.97 | EPS next Y | 0.10 | Insider Trans | -0.70% | Shs Float | 410.46M | Perf Month | -1.60% |
| Enterprise Value | 2.09B | PEG | — | EPS next Q | -0.01 | Short Float | 6.32% | Perf Quarter | 0.94% | ||
| Income | -18.00M | P/S | 0.92 | EPS this Y | — | Short Ratio | 6.10 | Perf Half Y | 62.64% | ||
| Sales | 2.48B | P/B | 6.09 | EPS next Y | 82.94% | ROA | -2.55% | Short Interest | 25.95M | Perf YTD | 83.40% |
| Book/sh | 0.71 | P/C | 11.39 | EPS next 5Y | 44.64% | ROE | -5.38% | 52W High | 5.59 -22.72% | Perf Year | 24.21% |
| Cash/sh | 0.38 | P/FCF | 30.94 | EPS past 3/5Y | — | ROIC | -4.63% | 52W Low | 1.58 173.42% | Perf 3Y | 353.73% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 20.60% 23.38% | Gross Margin | 18.57% | Volatility | 4.35% 4.90% | Perf 5Y | -42.91% |
| Dividend TTM | — | EV/Sales | 0.84 | EPS Y/Y TTM | — | Oper. Margin | -0.74% | ATR (14) | 0.22 | Perf 10Y | — |
| Dividend Ex-Date | Aug 23, 2021 | Quick Ratio | 1.50 | Sales Y/Y TTM | 54.04% | Profit Margin | -0.74% | RSI (14) | 41.04 | Recom | 3.22 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.50 | EPS Q/Q | — | SMA20 | -7.06% | Beta | 2.48 | Target Price | 5.63 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | 55.44% | SMA50 | -4.43% | Rel Volume | 1.18 | Prev Close | 4.31 |
| Employees | 724 | LT Debt/Eq | 0.00 | Earnings | Nov 04 | SMA200 | 21.42% | Avg Volume | 4.23M | Price | 4.32 |
| IPO Date | Jun 12, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 29.40% 2.05% | Net Debt/EBITDA | — | Volume | 5,004,187 | Change | 0.23% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-28-26 | Initiated | Needham | Buy | $6.00 |
| Sep-10-26 | Initiated | Deutsche Bank | Buy | $6.00 |
| Aug-06-26 | Reiterated | UBS | Neutral | $4.75 → $5.00 |
| Jul-21-26 | Reiterated | Canaccord Genuity | Buy | $4.20 → $5.50 |
| Jun-11-26 | Reiterated | UBS | Neutral | $4.75 |
| Jun-04-26 | Reiterated | Canaccord Genuity | Buy | $2.50 → $4.20 |
| Oct-21-25 | Reiterated | Leerink Partners | $3.00 | |
| Dec-17-24 | Initiated | Craig-Hallum | Buy | $6.00 |
| Aug-06-24 | Reiterated | Canaccord Genuity | Buy | $2.50 |
| Nov-16-22 | Reiterated | Citigroup | Neutral | $1.80 |
Latest News· Times ET
Oct-28-26
Oct-28-2604:38AM
Oct-26-26
Oct-26-2604:05PM
Oct-20-26
Oct-20-2604:22AM
04:22AM
04:22AM
Oct-19-26
Oct-19-2604:30PM
Oct-13-26
Oct-09-26
Oct-08-26
Oct-08-2606:45PM
06:00AM
Oct-07-26
Oct-07-2604:05PM
Oct-01-26
08:00AM
Sep-25-26
Sep-24-26
Sep-24-2605:55PM
Company
Clover Health Investments, Corp. is a U.S.-based firm specializing in Medicare Advantage insurance. The company leverages its proprietary software platform, the Clover Assistant, to provide both Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) health plans for individuals eligible for Medicare. In addition to its insurance operations, Clover Health also engages in non-insurance-related business ventures. The company was established in 2014 and its main office is located in Franklin, Tennessee.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,477 | 1,924 | 1,371 | 1,261 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,016 | 1,568 | 1,006 | 1,005 | — | — | — | — | — | |
| Gross Profit | 460 | 356 | 365 | 256 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 213 | 176 | 409 | 440 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 266 | 265 | 2 | 21 | — | — | — | — | — | |
| Operating Income | -18 | -86 | -46 | -205 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 0 | -1 | -5 | — | — | — | — | — | |
| Net Income Before Taxes | -18 | -86 | -46 | -210 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -18 | -86 | -43 | -213 | — | — | — | — | — | |
| Net Income From Continuing Operations | -18 | -86 | -46 | -210 | — | — | — | — | — | |
| Net Income | -18 | -86 | -43 | -213 | — | — | — | — | — | |
| EPS (Recurring) | -0.04 | -0.17 | -0.09 | -0.45 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.04 | -0.17 | -0.09 | -0.45 | — | — | — | — | — | |
| EPS (Diluted) | -0.04 | -0.17 | -0.09 | -0.45 | — | — | — | — | — | |
| EBITDA | -16 | -84 | -45 | -208 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.91 | 0.63 | 1.13 | 0.36 | — | — | — | — | — | |
| Gross Margin | 18.57 | 18.50 | 26.62 | 20.30 | — | — | — | — | — | |
| Operating Margin | -0.73 | -4.47 | -3.36 | -16.26 | — | — | — | — | — | |
| Net Margin | -0.73 | -4.47 | -3.14 | -16.89 | — | — | — | — | — | |
| Shares Outstanding | 524 | 517 | 490 | 482 | — | — | — | — | — | |
| Market Capitalization | 2,264 | 1,215 | 1,544 | 459 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Soares Karen | Chief Legal Officer | Oct 20 '26 | Sale | 4.66 | 19,275 | 89,822 | 1,573,423 | Oct 20 |
| Reynoso Jamie L. | CEO, Medicare Advantage | Oct 19 '26 | Sale | 4.41 | 4,066 | 17,931 | 2,770,351 | Oct 20 |
| Soares Karen | Chief Legal Officer | Oct 15 '26 | Sale | 4.68 | 14,673 | 68,670 | 1,592,698 | Oct 19 |
| THORNTON JOSEPH CLAY | Interim CFO | Oct 15 '26 | Sale | 4.68 | 4,591 | 21,486 | 1,244,935 | Oct 19 |
| Wai Conrad | CEO, Counterpart Health | Oct 15 '26 | Sale | 4.68 | 23,627 | 110,574 | 1,042,072 | Oct 19 |
| Reynoso Jamie L. | CEO, Medicare Advantage | Oct 15 '26 | Sale | 4.68 | 18,273 | 85,518 | 2,774,417 | Oct 19 |
| Toy Andrew | Chief Executive Officer | Oct 15 '26 | Sale | 4.68 | 62,176 | 290,984 | 9,078,334 | Oct 19 |
| Reynoso Jamie L. | CEO, Medicare Advantage | Oct 07 '26 | Sale | 4.63 | 2,006 | 9,288 | 2,792,690 | Oct 07 |
| Reynoso Jamie L. | CEO, Medicare Advantage | Oct 05 '26 | Sale | 4.42 | 8,750 | 38,675 | 2,794,696 | Oct 05 |
| Toy Andrew | Chief Executive Officer | Oct 01 '26 | Sale | 4.19 | 318,806 | 1,335,797 | 9,140,510 | Oct 02 |
| Reynoso Jamie L. | CEO, Medicare Advantage | Sep 17 '26 | Sale | 4.56 | 1,921 | 8,760 | 2,803,446 | Sep 18 |
| OLDAKOWSKI JOSEPH FRANK | VP OF FINANCE AND CONTROLLER | Sep 16 '26 | Sale | 4.64 | 3,170 | 14,709 | 275,897 | Sep 17 |
| Wai Conrad | CEO, Counterpart Health | Sep 15 '26 | Sale | 4.72 | 300,000 | 1,416,000 | 1,170,056 | Sep 16 |
| Soares Karen | Chief Legal Officer | Sep 15 '26 | Sale | 4.78 | 6,846 | 32,724 | 1,607,371 | Sep 15 |
| Reynoso Jamie L. | CEO, Medicare Advantage | Sep 15 '26 | Sale | 4.78 | 9,273 | 44,325 | 2,805,367 | Sep 15 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.